Outlook Wealth Advisors LLC Boosts Stake in Zoetis Inc. (NYSE:ZTS)

Outlook Wealth Advisors LLC lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 66.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,371 shares of the company’s stock after acquiring an additional 2,153 shares during the quarter. Outlook Wealth Advisors LLC’s holdings in Zoetis were worth $875,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of ZTS. Cherry Creek Investment Advisors Inc. grew its holdings in Zoetis by 2.0% during the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock worth $590,000 after acquiring an additional 58 shares in the last quarter. Grove Bank & Trust lifted its position in shares of Zoetis by 0.5% during the third quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock worth $2,298,000 after purchasing an additional 61 shares during the last quarter. Hancock Whitney Corp grew its stake in Zoetis by 0.3% in the third quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock worth $3,628,000 after purchasing an additional 61 shares in the last quarter. Strategy Asset Managers LLC increased its holdings in Zoetis by 3.5% in the third quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock valued at $356,000 after buying an additional 62 shares during the last quarter. Finally, Edge Capital Group LLC raised its stake in Zoetis by 3.7% during the second quarter. Edge Capital Group LLC now owns 1,786 shares of the company’s stock valued at $310,000 after buying an additional 64 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $167.23 on Thursday. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The firm has a market capitalization of $75.45 billion, a price-to-earnings ratio of 31.43, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89. The business has a 50 day simple moving average of $171.31 and a 200 day simple moving average of $180.16.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.36 earnings per share. On average, equities research analysts anticipate that Zoetis Inc. will post 5.91 EPS for the current year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be paid a $0.50 dividend. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.20%. The ex-dividend date of this dividend is Tuesday, January 21st. Zoetis’s dividend payout ratio is currently 32.52%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ZTS. Stifel Nicolaus lowered their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. raised their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Finally, UBS Group assumed coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. One analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $211.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.